Table 6.
aGVHD- and cGVHD-free survival
| Variables | aGVHD-free survival (n = 34) | cGVHD-free survival (n = 37) | ||
|---|---|---|---|---|
| Percent (95% CI) | p value* | Percent (95% CI) | p value* | |
| Age at ECP | ||||
| ≥Median | 37 (20-70) | 0.32 | 22 (9-53) | 0.74 |
| <Median | 61 (42-88) | 47 (29-76) | ||
| Sex | ||||
| Male | 44 (25-76) | 0.43 | 25 (13-47) | 0.01 |
| Female | 56 (37-84) | 67 (42-100) | ||
| Stem cell source | ||||
| BM | 54 (37-80) | 0.65 | 47 (28-78) | 0.67 |
| PB | 33 (13-84) | 25 (12-53) | ||
| CB | 67 (30-100) | NA | ||
| Sex mismatch | ||||
| Female > male | 57 (30-100) | 0.52 | 22 (9-53) | 0.23 |
| Other | 48 (32-71) | 53 (34-83) | ||
| GVHD grade | ||||
| II | 81 (64-100) | 0.0008 | NA | |
| III | 33 (15-74) | NA | ||
| IV | 0 | NA | ||
| Donor type | ||||
| MFD | 42 (27-66) | 0.11 | 27 (14-51) | 0.14 |
| MUD | 75 (50-100) | 54 (32-93) | ||
| First-line therapy | ||||
| Steroids | 56 (41-77) | 0.11 | NA | |
| Steroids plus other | 0 | NA | ||
| Visceral aGVHD | ||||
| Yes | 33 (57-100) | 0.03 | NA | |
| No | 77 (18-61) | NA | ||
| cGVHD onset | ||||
| De novo | NA | 50 (28-88) | 0.30 | |
| Quiescent | NA | 28 (12-65) | ||
| Progressive | NA | 27 (10-71) | ||
| Seattle criteria | ||||
| Limited | NA | 67 (45-91) | 0.003 | |
| Extensive | NA | 20 (9-44) | ||
| NIH criteria | ||||
| Mild | NA | 57 (36-90) | 0.07 | |
| Moderate | NA | 28 (13-58) | ||
| Severe | NA | 0 | ||
| CIBMTR criteria | ||||
| RG1 | NA | 50 (27-94) | 0.85 | |
| RG2 | NA | 32 (18-57) | ||
| ≥RG3 | NA | 0 | ||
| TNCs/kg | ||||
| ≥Median | 46 (26-83) | 0.68 | 37 (20-70) | 0.53 |
| <Median | 43 (23-78) | 40 (21-74) | ||
| Lymphocytes/kg | ||||
| ≥Median | 43 (23-78) | 0.95 | 50 (31-82) | 0.60 |
| <Median | 46 (26-83) | 27 (11-62) | ||
| WBCs before ECP | ||||
| ≥Median | 56 (37-84) | 0.94 | 47 (29-76) | 0.21 |
| <Median | 44 (25-76) | 22 (9-53) | ||
| Lymphocytes before ECP | ||||
| ≥Median | 57 (36-90) | 0.72 | 42 (25-71) | 0.57 |
| <Median | 44 (25-76) | 28 (13-58) | ||
| Monocytes before ECP | ||||
| ≥Median | 45 (28-73) | 0.43 | 41 (23-72) | 0.45 |
| <Median | 57 (36-90) | 37 (20-71) | ||
| PLTs before ECP | ||||
| ≥Median | 53 (33-86) | 0.50 | 37 (20-66) | 0.70 |
| <Median | 47 (29-76) | 33 (17-64) | ||
* The p value for aGVHD-free survival and cGVHD-free survival was calculated according to the Gray test.35
BM = bone marrow; CB = cord blood; female > male = female donor for a male recipient; PB = peripheral blood.